- Healthcare (12)
- Litigation / Dispute Resolution (11)
- Company/Commercial (9)
- Intellectual Property (9)
- Corporate (7)
- Regulatory and compliance (5)
- Banking / Finance (4)
- Clinical/Medical Negligence (4)
- Information Technology (4)
- Commodities (3)
- Employment (3)
- Real Estate (3)
- Crime (2)
- Insurance/reinsurance (2)
- Media/Entertainment/Sport (2)
- Private Equity (2)
- Tax (2)
- Agriculture (1)
- Competition/EU (1)
- Energy (1)
- Environment (1)
- Funds (1)
- Public Sector/Local Authority (1)
- Telecoms (1)
Sort By: Newest first | Oldest first
Antitrust and competition enforcement is changing fast: our report for multinationals from three global conferences
The world of antitrust/competition enforcement is changing more rapidly than ever. This evolving environment presents new challenges for companies.
Amy Jensen Cunniffe has joined DLA Piper’s government affairs and healthcare public policy and regulatory practices as a senior policy adviser in Washington DC.
DLA Piper has advised Parnell Pharmaceuticals Holdings (PARN) in its initial public offering on NASDAQ.
DLA Piper has announced that Ben Boyd and Mary Gately have been named co-managing partners of the Washington DC office.
In food marketing litigation, class certification is a major hurdle for would-be class plaintiffs, but a recent case may have lowered the bar with a flexible approach to class certification.
DLA Piper has announced that Lisa Haile and Mark Fowler have been named to the Daily Journal’s 2014 list of ‘Top Intellectual Property Lawyers’.
DLA Piper has secured the dismissal of patent infringement claims against subsidiaries of St Jude Medical, a global medical device manufacturer, by Volcano Corp.
California GCI’s coming priority products list and the DTSC Strategic Plan — what do they mean for you?
The highly anticipated next step in California’s Green Chemistry Initiative (GCI) is the planned April 2014 release of the list of ‘priority products’.
DLA Piper has released the 3 February 2014 issue of its Health Alert, which focuses on judgments, legislation and reports in the health sector.
DLA Piper has released the 28 January 2014 issue of its Health Alert, which focuses on judgments, legislation and reports in the health sector.
DLA Piper has represented Arsenal Capital Partners in its purchase of Certara, a biopharmaceutical service provider.
DLA Piper advised on more than 20 significant inbound and outbound US transactions that closed last year on behalf of Israeli institutional investors and companies.
DLA Piper has announced that Wayne P Bunch Jr has joined the law firm’s franchise and distribution practice as a partner in the Houston office.
The Australian High Court has delivered its first judgment that directly considers the patentability of methods of medical treatment.
A recent decision by the Court of Appeal provides useful guidance on the correct approach to defining the market in relation to pharmaceutical products.
Despite 20 states allowing the use of medicinal marijuana and two more allowing recreational marijuana use, employers remain unaffected.
Antitrust agencies amend premerger notification rules to clarify reporting of acquisitions of pharmaceutical patent rights
The new rules may cause an uptick in premerger notification filings in the pharmaceutical industry.
Offering healthcare solutions at consumers' fingertips? What you should know about FDA regulation of mobile medical apps
More than two years after the FDA issued draft guidance on ‘mobile medical applications’, the agency recently issued its final guidance.
DLA Piper has published the second issue of its Life Sciences Spotlight publication for 2013.
The US Supreme Court has ruled that certain patent claims owned by Myriad Genetics are invalid as products of nature.